Show simple item record

dc.contributor.authorPuac-Polanco, Victor
dc.contributor.authorChihuri, Stanford
dc.contributor.authorFink, David S
dc.contributor.authorCerdá, Magdalena
dc.contributor.authorKeyes, Katherine M
dc.contributor.authorLi, Guohua
dc.date.accessioned2023-03-22T16:51:17Z
dc.date.available2023-03-22T16:51:17Z
dc.identifier.citationPuac-Polanco V, Chihuri S, Fink DS, Cerdá M, Keyes KM, Li G. Prescription Drug Monitoring Programs and Prescription Opioid-Related Outcomes in the United States. Epidemiol Rev. 2020 Jan 31;42(1):134-153. doi: 10.1093/epirev/mxaa002. PMID: 32242239; PMCID: PMC7947593.en_US
dc.identifier.eissn1478-6729
dc.identifier.doi10.1093/epirev/mxaa002
dc.identifier.pmid32242239
dc.identifier.urihttp://hdl.handle.net/20.500.12648/8529
dc.description.abstractPrescription drug monitoring programs (PDMPs) are a crucial component of federal and state governments' response to the opioid epidemic. Evidence about the effectiveness of PDMPs in reducing prescription opioid-related adverse outcomes is mixed. We conducted a systematic review to examine whether PDMP implementation within the United States is associated with changes in 4 prescription opioid-related outcome domains: opioid prescribing behaviors, opioid diversion and supply, opioid-related morbidity and substance-use disorders, and opioid-related deaths. We searched for eligible publications in Embase, Google Scholar, MEDLINE, and Web of Science. A total of 29 studies, published between 2009 and 2019, met the inclusion criteria. Of the 16 studies examining PDMPs and prescribing behaviors, 11 found that implementing PDMPs reduced prescribing behaviors. All 3 studies on opioid diversion and supply reported reductions in the examined outcomes. In the opioid-related morbidity and substance-use disorders domain, 7 of 8 studies found associations with prescription opioid-related outcomes. Four of 8 studies in the opioid-related deaths domain reported reduced mortality rates. Despite the mixed findings, emerging evidence supports that the implementation of state PDMPs reduces opioid prescriptions, opioid diversion and supply, and opioid-related morbidity and substance-use disorder outcomes. When PDMP characteristics were examined, mandatory access provisions were associated with reductions in prescribing behaviors, diversion outcomes, hospital admissions, substance-use disorders, and mortality rates. Inconsistencies in the evidence base across outcome domains are due to analytical approaches across studies and, to some extent, heterogeneities in PDMP policies implemented across states and over time.
dc.language.isoenen_US
dc.relation.urlhttps://academic.oup.com/epirev/article/42/1/134/5815326en_US
dc.rights© The Author(s) 2020. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectdrug prescriptionsen_US
dc.subjectopioid-related disordersen_US
dc.subjectprescription drug diversionen_US
dc.subjectprescription drug monitoring programsen_US
dc.subjectsubstance-related disordersen_US
dc.titlePrescription Drug Monitoring Programs and Prescription Opioid-Related Outcomes in the United States.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleEpidemiologic reviewsen_US
dc.source.volume42
dc.source.issue1
dc.source.beginpage134
dc.source.endpage153
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.description.versionVoRen_US
refterms.dateFOA2023-03-22T16:51:18Z
html.description.abstractPrescription drug monitoring programs (PDMPs) are a crucial component of federal and state governments' response to the opioid epidemic. Evidence about the effectiveness of PDMPs in reducing prescription opioid-related adverse outcomes is mixed. We conducted a systematic review to examine whether PDMP implementation within the United States is associated with changes in 4 prescription opioid-related outcome domains: opioid prescribing behaviors, opioid diversion and supply, opioid-related morbidity and substance-use disorders, and opioid-related deaths. We searched for eligible publications in Embase, Google Scholar, MEDLINE, and Web of Science. A total of 29 studies, published between 2009 and 2019, met the inclusion criteria. Of the 16 studies examining PDMPs and prescribing behaviors, 11 found that implementing PDMPs reduced prescribing behaviors. All 3 studies on opioid diversion and supply reported reductions in the examined outcomes. In the opioid-related morbidity and substance-use disorders domain, 7 of 8 studies found associations with prescription opioid-related outcomes. Four of 8 studies in the opioid-related deaths domain reported reduced mortality rates. Despite the mixed findings, emerging evidence supports that the implementation of state PDMPs reduces opioid prescriptions, opioid diversion and supply, and opioid-related morbidity and substance-use disorder outcomes. When PDMP characteristics were examined, mandatory access provisions were associated with reductions in prescribing behaviors, diversion outcomes, hospital admissions, substance-use disorders, and mortality rates. Inconsistencies in the evidence base across outcome domains are due to analytical approaches across studies and, to some extent, heterogeneities in PDMP policies implemented across states and over time.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentEpidemiology and Biostatisticsen_US
dc.description.departmentHealth Policy and Managementen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalEpidemiologic reviews


Files in this item

Thumbnail
Name:
mxaa002.pdf
Size:
443.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2020. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Except where otherwise noted, this item's license is described as © The Author(s) 2020. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.